- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Emerald Health Therapeutics’ Scientific Advisors Publish Research Discovery
Emerald Health Therapeutics announced members of its scientific advisory team made a discovery showing the potential of tetrahydrocannabinolic acid to treat Huntington’s disease and other metabolic, neurodegenerative and neuroinflammatory diseases.
Emerald Health Therapeutics (TSXV:EMH; OTCQX:EMHTF) announced members of its scientific advisory team made a discovery showing the potential of tetrahydrocannabinolic acid to treat Huntington’s disease and other metabolic, neurodegenerative and neuroinflammatory diseases.
As quoted in the press release:
These results were published in the British Journal of Pharmacology in a peer-reviewed article entitled, “Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.”
This recent article in the British Journal of Pharmacology focused on the activity of Δ9-THCA, one of the most common cannabinoids (and a non-psychotropic precursor of THC), on PPARγ. PPARγ signalling has a role in neuroinflammation and epilepsy. Δ9-THCA is a potent PPARγ agonist and in this study exhibited neuroprotective and anti-neuroinflammatory activity in an animal model of Huntington´s disease.
This research was conducted at Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC). Co-authors of this paper included EHT scientific advisory board members Eduardo Muñoz, MD, PhD, Professor of Immunology at University of Córdoba; Giovanni Appendino, PhD, Professor of Pharmaceutical Chemistry at University of Eastern Piedmont; and Gaetano Morello, ND, clinician, Complex Chronic Disease Program, BC Women’s Hospital.
Click here to read the full press release.
Source: globenewswire.com
Outlook Reports
Featured Cannabis Investing News Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2388.69 | +6.89 | |
Silver | 28.20 | -0.69 | |
Copper | 4.30 | -0.08 | |
Oil | 85.28 | -0.13 | |
Heating Oil | 2.66 | 0.00 | |
Natural Gas | 1.74 | +0.05 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.